Form 4 for ALZN Alzamend Neuro, Inc.
Accepted 2022-04-06 00:00:00 ET · period of report 2022-03-28 · accession 0001214659-22-004914 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-04-06 | 2022-03-28 | ALZN | McGrath Lynne Fahey | Dir | S - Sale | $1.21 | +25.0K | 75.0K | +50% | +$30.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-28 | S | A | 25,000 | $1.21 | 75,000 | D | — | — | (F1) The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average purchase price of $1.213. The range of sale prices on the transaction date was $1.19 to $1.23 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. |